YWYongxia Wang

Yongxia Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yongxia Wang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Mingjun Zhu

    Department of Cardiovascular Disease, The first Affiliated Hospital of Henan University of Chinese Medicine

    8 shared publications
  • Genhao Fan

    Cardiac Center, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

    7 shared publications
  • Bin Li

    Heart Center, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

    5 shared publications
  • Xinlu Wang

    Department of Cardiovascular Disease, The first Affiliated Hospital of Henan University of Chinese Medicine

    5 shared publications
  • Jingjing Wei

    Heart Center, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China

    3 shared publications
  • Jingjing Wei

    Department of Cardiovascular Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, People’s Republic of China

    3 shared publications

Latest Publications

  • Open Access

    The bidirectional genetic causality between immunocyte phenotypes and dilated cardiomyopathy: A bidirectional Mendelian randomization study

    by Wenshuai Feng, Xindi Chang, Qiaozhi Li, Zhengwei Dong, Ge Jin, Jinyu Huang, Genhao Fan, Zuoying Xing, Yongxia Wang

    The association between immunocyte phenotypes and dilated cardiomyopathy (DCM) has been explored, however the exact pathogenesis of the relationship between immune cells and DCM is unclear. This bidirectional two-sample Mendelian randomization (MR) research aims to further validate the causal link between 731 immunocyte phenotypes and DCM. Summary statistics from a genome-wide association study data of individuals with European ancestry were utilized, including 1444 DCM cases and 353,937 controls, as well as 3757 European adults for the 731 immunocyte phenotypes. Causal effects were estimated using inverse variance weighted, MR-Egger regression, weight median estimator, weighted mode, and simple mode. Sensitivity analysis was conducted to confirm data robustness and feasibility. Based on the inverse variance weighted findings, 14 immunocyte phenotypes were risk factors for DCM ( P < .05, odds ratio [OR] > 1), while 15 immunocyte phenotypes exhibited a protective effect on DCM ( P < .05, OR < 1). The results of reverse MR analysis suggested evidence that DCM occurrence might elevate the levels of 17 immunocyte phenotypes ( P < .05, OR > 1) and decrease the levels of 9 immunocyte phenotypes ( P < .05, OR < 1). Our research indicated that CD28 on secreting regulatory T cell could mitigate the occurrence of DCM, and reciprocally, the progression of DCM could reduce the level of CD28 on secreting regulatory T cell. This study confirmed the bidirectional genetic predictive relationship between immunocyte phenotypes and DCM, underscoring the complex interplay between DCM and the immune system.

  • Open Access

    Piceatannol-3′-O-β-d-glucopyranoside mitigates myocardial ischemia-reperfusion injury by inhibiting ferroptosis through the regulation of NDUFS1 lactylation via metabolic reprogramming

    by Genhao Fan, Chidao Zhang, Wenqing Zhang, Xuli Ji, Menglin Liu, Peng Chen, Boyong Qiu, Yankun Song, Min Zhang, Teng Ma, et al.


  • Open Access

    Association between fibrosis-4 index and coronary heart disease: a population-based study

    by Pan Jia, Mamajan Annamyradova, Genhao Fan, Qizhen Zhang, Yankun Song, Qiaozhi Li, Minghao Liu, Zuoying Xing, Yongxia Wang

    Although the fibrosis-4 index (FIB‐4) was initially established as a liver fibrosis marker, recent studies have demonstrated its significant association with elevated risk of coronary artery disease(CHD). This study was conducted using data from five National Health and Nutrition Examination Surveys (NHANES) cycles between 2009 and 2018. Multivariable logistic regression analysis revealed a significant, positive relationship between FIB-4 and CHD.In sensitivity analyses, the highest FIB-4 quartile (Q4) showed a 4.22-fold increased CHD risk versus Q1 (OR = 4.22, 95% CI:1.93–9.24, P = 0.0005), with significant dose-response trends across quartiles (P < 0.05). Receiver operating characteristic (ROC) analysis revealed FIB-4 had good discriminative power for CHD (AUC = 0.80, 95%CI:0.78–0.81), with 75.9% sensitivity and 30.2% specificity at the optimal cutoff of 1.31. Restricted cubic splines (RCS) analysis revealed a nonlinear dose-response relationship between FIB-4 and CHD risk (P < 0.0001), with accelerated risk elevation beyond the inflection point (FIB-4 = 2.73). Subgroup analyses confirmed FIB-4’s robust association with CHD risk (overall OR = 1.66, 95%CI:1.57–1.76), with stronger effects in males (vs. females, Pinteraction = 0.042), non-diabetics (vs. diabetics, Pinteraction < 0.001), and racial minorities (highest OR = 2.36 in ‘Other Race’).These findings underscore the potential of FIB-4 as a novel biomarker for CHD risk assessment in clinical practice.


  • Open Access

    CLU, FOS, and CXCL8 as diagnostic biomarkers for heart failure progression post-acute myocardial infarction: an integrated RNA-Seq and multi-machine learning study

    by Jingjing Wei, Peng Yu, Yucai Hu, Lijie Qiao, Bin Li, Haitao Li, Shiyang Xie, Zhengwei Dong, Aolong Wang, Yilin Zhang, et al.

    Background: Heart failure (HF) secondary to acute myocardial infarction (AMI) remains a public health concern. Peripheral blood mononuclear cells (PBMCs) are the essential initiators of heart failure after myocardial infarction (HFpAMI). We aimed to identify PBMCs-related critical genes as diagnostic biomarkers for HFpAMI and analyze the immune infiltration patterns.Methods: Differential expression genes (DEGs) from PBMCs microarray data of AMI with or without HF were identified. Functional enrichment analysis was used to explore the biological roles of DEGs. Subsequently, candidate biomarkers were identified using machine learning and the MCODE plugin, with ROC used to describe the accuracy. CIBERSORT was utilized to investigate immune infiltration. Multi-level validation of our findings was conducted, including RNA-seq profiling of the external cohort, RT-qPCR, and flow cytometry analyses on PBMCs samples.Results: In the comparison between 30 HFpAMI and 34 non-HF samples, 27 DEGs were identified. Functional enrichment analysis suggested that DEGs may be involved in the pathological process of HFpAMI by participating in immune-inflammatory response. Employing machine learning and MCODE assessment, we identified three robust potential biomarkers (CLU, FOS, and CXCL8). Immunological analysis revealed a marked increase in neutrophils and decrease in CD4T cells. In the external validation cohort, RNA-seq analysis demonstrated consistent upregulation of CLU, FOS, and CXCL8 in HFpAMI compared to non-HF controls. RT-qPCR and flow cytometry further corroborated these expression trends and their correlations with neutrophil infiltration, CD4T cells and M2 macrophage concentration reductio, aligning with bioinformatics predictions. ROC analysis validated the diagnostic efficacy of these biomarkers, with CLU exhibiting the highest AUC (0.833, 95% CI: 0.679–0.988), followed by FOS (0.809, 95% CI: 0.64–0.977) and CXCL8 (0.802, 95% CI: 0.635–0.970).Conclusions: Significantly upregulated DEGs, including CLU, FOS, and CXCL8, might be served as novel diagnostic biomarkers for HFpAMI, and dysregulated immune infiltration hinted possible the immune system intervention point in the setting of HFpAMI.


  • Open Access

    Causal relationship between inflammatory bowel disease and cardiovascular disease: a two-sample Mendelian randomized study

    by Lianghao Ma, Lishan Ding, Zuoying Xing, Hongjie Ren, Jingjing Wei, Huanhuan Song, Boyong Qiu, Zhaoqi Chen, Yongxia Wang

    Introduction: Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). Epidemiological studies have found that patients with IBD are more likely to suffer from cardiovascular diseases (CVDs) than the general population. However, so far, no exact causal association has been demonstrated between IBD and CVDs, and more research is needed to clarify this relationship.Material and methods: The two-sample Mendelian randomization (MR) method was used to explore the causal effect of IBD on CVDs. The exposure factor was IBD, including CD and UC. The outcome was CVDs, including chronic heart failure, atrial fibrillation, coronary heart disease, myocardial infarction and hypertension. The single nucleotide polymorphisms (SNPs) are all from the FinnGen genome-wide association study sample database. The CD samples included 210,300 controls and 807 cases, and the UC samples included 215,806 controls and 2701 cases. The samples included are all European samples. SNPs associated with Crohn’s disease and ulcerative colitis were extracted from the IEUGWAS database and quality control and screening were carried out. Inverse variance weighted (IVW), MR-Egger, weighted median and other methods were used to study the causal relationship between them and CVDs. Finally, Cochrane’s Q test, MR-Egger and the leave-one method were used for sensitivity analysis.Results: In this study, 4 SNPs strongly associated with Crohn’s disease and 12 SNPs strongly associated with ulcerative colitis were screened. The IVW method of genetic prediction revealed a positive correlation between Crohn’s disease and the risk of chronic heart failure (OR =1.02; 95% CI: 1.00–1.04), and there was a positive correlation between ulcerative colitis and the risk of chronic heart failure (OR = 1.03; 95% CI:1.00–1.06). IVW, MR-Egger and weighted median showed that Crohn’s disease and ulcerative colitis were not associated with the risk of atrial fibrillation, coronary heart disease, myocardial infarction or hypertension. Sensitivity analysis showed that the results are robust.Conclusions: Crohn’s disease and ulcerative colitis are associated with an increased risk of chronic heart failure, but they are not associated with the risk of other CVDs.


  • Open Access

    Pathological mechanisms and crosstalk among various cell death pathways in cardiac involvement of systemic lupus erythematosus

    by Jingjing Wei, Aolong Wang, Bin Li, Xingyuan Li, Rui Yu, Haitao Li, Xinlu Wang, Yongxia Wang, Mingjun Zhu

    Systemic lupus erythematosus (SLE) is a prevalent autoimmune disease primarily characterized by the involvement of multiple systems and organs. Cardiovascular disease is the primary cause of mortality in patients with SLE, though the mechanisms underlying the increased cardiovascular risk in SLE patients remain unclear. Recent studies indicate that abnormal activation of programmed cell death (PCD) signaling and the crosstalk among various forms of cell death are critical in the immunopathogenesis of SLE. Furthermore, apoptosis, necroptosis, pyroptosis, NETosis, and ferroptosis are recognized as key cellular processes in the pathogenesis of SLE and are closely linked to cardiac involvement. This review uniquely explores the intricate crosstalk between apoptosis, necroptosis, and other cell death pathways, discussing their roles and interactions in the pathogenesis of cardiac involvement in SLE. Investigating the interplay between PCD signaling and cardiac involvement in SLE in understanding the disease’s underlying mechanisms and offers opportunities for new therapeutic interventions. The integration of precision medicine and innovative strategies targeting these complex pathways holds promise for enhancing the treatment prospects of SLE with cardiac involvement.


  • Open Access

    Effect of adjuvant therapy with compound danshen drip pill on inflammatory factors and cardiac function after percutaneous coronary intervention for acute myocardial infarction: a systematic review and meta-analysis

    by Genhao Fan, Menglin Liu, Huanhuan Song, Yongxia Wang

    Objectives: The purpose of the study was to comprehensively evaluate efficacy and safety of CDDP in patients with AMI undergoing PCI.Methods: A computerised search was conducted on the CNKI, WF, VIP, CBM, PubMed, Embase, Web of Science, and Cochrane Library databases for RCTs of CDDP adjuvant therapy for AMI up to May 2023. STATA 17.0 was used to perform meta-analyses, sensitivity analyses, subgroup analyses, meta-regression, and publication bias assessments. TSA 0.9.5.10 Beta was used for trial sequential analysis (TSA). Evidence confidence of meta results was evaluated by GRADE (Grading of Recommendations Assessment, Development and Evaluation) according to the instructions.Results: The results of the meta-analysis showed that CDDP combined with conventional western treatment (CWT) was superior to CWT in increasing LVEF and TCER and decreasing LVEDD, hs-CRP, IL-6 and TNF-α. The quality of evidence for TCER was moderate, LVEF, LVEDD, IL-6, and TNF-α were low. The TSA results showed that the total number of samples collected in this study met the requirements for meta-analysis and excluded the possibility of false positives, further confirming the efficacy of CDDP for the treatment of AMI undergoing PCI.Conclusion: Adjuvant treatment of AMI with CDDP has shown exciting and safe benefits in improving cardiac function and reducing inflammatory response in patients with AMI undergoing PCI, but the quality of some of the included studies was poor, and the results should be interpreted with caution until further confirmation by well-designed RCTs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/#recordDetails], identifier [CRD42023453293].